SG11201900279UA - Long-acting coagulation factor vii and methods of producing same - Google Patents

Long-acting coagulation factor vii and methods of producing same

Info

Publication number
SG11201900279UA
SG11201900279UA SG11201900279UA SG11201900279UA SG11201900279UA SG 11201900279U A SG11201900279U A SG 11201900279UA SG 11201900279U A SG11201900279U A SG 11201900279UA SG 11201900279U A SG11201900279U A SG 11201900279UA SG 11201900279U A SG11201900279U A SG 11201900279UA
Authority
SG
Singapore
Prior art keywords
international
coagulation factor
methods
pct
producing same
Prior art date
Application number
SG11201900279UA
Inventor
Oren Hershkovitz
Laura Moschcovich
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of SG11201900279UA publication Critical patent/SG11201900279UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 0111111 01110101111101110 111110 HOE lil Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/011799 Al 18 January 2018 (18.01.2018) WIP0 I PCT (51) International Patent Classification: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, C07K 14/59 (2006.01) C07K 14/61 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (21) International Application Number: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, PCT/IL2017/050784 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 11 July 2017 (11.07.2017) kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (25) Filing Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (26) Publication Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (30) Priority Data: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 62/360,767 11 July 2016 (11.07.2016) US TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (71) Applicant: OPKO BIOLOGICS LTD. [IL/IL]; 6 Ashle- gan Street, 8211804 Kiryat Gat (IL). Published: (72) Inventors: HERSHKOVITZ, Oren; P.O.B. 215, M.P. — with international search report (Art. 21(3)) Shikmim, 7982000 Kibbutz Revadim (IL). MOSCHCOV- — with sequence listing part of description (Rule 5.2(a)) ICH, Laura; Sireni 6, 5401844 Givat Shmuel (IL). (74) Agent: VAN DER BOOM, Tamar et al.; Pearl Cohen _ Zedek Latzer Baratz, P.O. Box 7198, Tel Aviv 6107121 (IL). = Designated States (unless otherwise indicated, for every (81) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = _ = = — HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Title: LONG-ACTING COAGULATION FACTOR VII AND METHODS OF PRODUCING SAME (54) = FIGURE 1 CMV enhancer/promotor = Xbal(1115) = = = — beta lactamase (Amp r) coding region pCI-dhfr-MOD- - 5014 MOD-5014 — = 6892 bp Noth2728) — 1-1 Synthetic polyadenylation signal SV40 late polyadenylation signal dhf 01 01 Phage fl region Ir--- 1-1 SV40 enhancer and early promotor 1-1 0 --.... 00 1-1 (57) : Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy el terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions and pharmaceutical formulations comprising the polypeptides and polynucleotides of the disclosure and methods of using 0 and producing same are also disclosed.
SG11201900279UA 2016-07-11 2017-07-11 Long-acting coagulation factor vii and methods of producing same SG11201900279UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662360767P 2016-07-11 2016-07-11
PCT/IL2017/050784 WO2018011799A1 (en) 2016-07-11 2017-07-11 Long-acting coagulation factor vii and methods of producing same

Publications (1)

Publication Number Publication Date
SG11201900279UA true SG11201900279UA (en) 2019-02-27

Family

ID=59656113

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202100189WA SG10202100189WA (en) 2016-07-11 2017-07-11 Long-acting coagulation factor vii and methods of producing same
SG11201900279UA SG11201900279UA (en) 2016-07-11 2017-07-11 Long-acting coagulation factor vii and methods of producing same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202100189WA SG10202100189WA (en) 2016-07-11 2017-07-11 Long-acting coagulation factor vii and methods of producing same

Country Status (17)

Country Link
US (1) US11976106B2 (en)
EP (2) EP3481855B1 (en)
JP (1) JP7319187B2 (en)
KR (2) KR102618424B1 (en)
CN (2) CN109563145B (en)
AU (3) AU2017296352A1 (en)
BR (1) BR112019000610A2 (en)
CA (1) CA3030533A1 (en)
CL (1) CL2019000099A1 (en)
EA (1) EA201990255A1 (en)
ES (1) ES2963725T3 (en)
HU (1) HUE064463T2 (en)
IL (2) IL264208B1 (en)
MX (1) MX2019000554A (en)
PT (1) PT3481855T (en)
SG (2) SG10202100189WA (en)
WO (1) WO2018011799A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same
US20220273566A1 (en) * 2019-07-29 2022-09-01 Georgia Tech Research Corporation Nanomaterials containing constrained lipids and uses thereof

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS5781447A (en) 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (en) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
DE3584341D1 (en) 1984-08-24 1991-11-14 Upjohn Co RECOMBINANT DNA COMPOUNDS AND EXPRESSION OF POLYPEPTIDES LIKE TPA.
US4911691A (en) 1984-09-21 1990-03-27 Menlo Care, Inc. Assembly for adminstering IV solution
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
JP2874751B2 (en) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション Transgenic animals secreting the desired protein into milk
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
ATE110571T1 (en) 1988-05-06 1994-09-15 Toray Industries STABLE INTERFERON BETA COMPOSITION.
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5792460A (en) 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
AU648020B2 (en) 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5705478A (en) 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5338835A (en) 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US6028177A (en) 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
NZ265529A (en) 1993-04-20 1998-01-26 Univ Washington Peptide/protein modified with insertion of complete or partial carboxy terminal peptide unit into a non critical region
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5824642A (en) 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
BR9506313A (en) 1994-08-12 1997-08-05 Univ Washington Single chain forms of the glycoprotein hormone quartet
DE19539493A1 (en) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Strong homologous promoter from hamster
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL122732A0 (en) 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6103501A (en) 1997-11-17 2000-08-15 Washington University Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof
CA2343094A1 (en) 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
KR100882544B1 (en) 1999-05-24 2009-02-12 미쓰비시 타나베 파마 코퍼레이션 Phenoxypropylamine compounds
PE20010288A1 (en) 1999-07-02 2001-03-07 Hoffmann La Roche ERYTHROPOYETIN DERIVATIVES
US20010028895A1 (en) 2000-02-04 2001-10-11 Bisgaier Charles L. Methods of treating alzheimer's disease
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US20030036181A1 (en) 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2002220002B2 (en) 2000-10-31 2006-12-14 Evonik Corporation Methods and compositions for enhanced delivery of bioactive molecules
EP1335938B1 (en) 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
WO2002043709A1 (en) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Method for producing preparation containing bioactive substance
US7271149B2 (en) 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
AU2002222740A1 (en) 2000-12-11 2002-06-24 Cheil Jedang Corporation Fusion protein having the enhanced in vivo activity of erythropoietin
KR101229995B1 (en) 2000-12-11 2013-02-06 씨제이 주식회사 Fusion protein having the enhanced in vivo activity of erythropoietin
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
US6987172B2 (en) 2001-03-05 2006-01-17 Washington University In St. Louis Multifunctional single chain glycoprotein hormones comprising three or more β subunits
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AU2002338436A1 (en) 2001-04-25 2002-11-05 Hernan F. Acevedo Hcg formulation
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
DK1440157T3 (en) 2001-10-29 2012-05-07 Crucell Holland Bv METHODS AND MEANS FOR PRODUCING PROTEINS WITH PREDETERMINED POST-TRANSLATIONAL MODIFICATIONS
KR100511749B1 (en) 2001-11-06 2005-09-02 선바이오(주) Modified interferon-beta, and chemically modified conjugates thereof
KR100467750B1 (en) 2001-11-29 2005-01-24 씨제이 주식회사 Fusion protein having the enhanced in vivo activity of erythropoietin
KR100467751B1 (en) 2001-12-03 2005-01-24 씨제이 주식회사 Fusion protein having the enhanced in vivo erythropoietin activity
ES2545090T3 (en) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
GB0206048D0 (en) 2002-03-14 2002-04-24 Croda Int Plc Use
WO2003094858A2 (en) 2002-05-13 2003-11-20 Modigenetech Ltd. Ctp-extended erythropoietin
US20070298041A1 (en) 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
RS20050035A (en) 2002-07-17 2007-06-04 Biogen Idec Ma Inc., Therapies for renal failure using interferon-betha
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
EP2460530A3 (en) 2002-12-31 2012-08-29 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them
WO2004073749A1 (en) 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited Dispersant for sustained release preparations
PL1620118T3 (en) 2003-04-08 2014-11-28 Yeda Res & Dev Reversible pegylated drugs
JP4915918B2 (en) 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー Gla domain variants of factor VII or factor VIIa
CN1245510C (en) 2003-09-25 2006-03-15 复旦大学 Long-acting reconbinant tissue factor channel inhibitor and preparing method thereof
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
CN1243022C (en) 2003-10-17 2006-02-22 华东师范大学 Biological modifying and recombinant human growth hormone compound and preparing method thereof
WO2005047319A2 (en) 2003-11-12 2005-05-26 The University Of Georgia Research Foundation, Inc. Dna sequence and expressed recombinant glycoproteins related to feline thyrotropin
PL1696947T3 (en) 2003-12-19 2014-08-29 Hoffmann La Roche Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
ES2357132T3 (en) 2004-03-19 2011-04-19 Baxter International Inc. IXA FACTOR FOR THE TREATMENT OF HEMORRHAGICAL DISORDERS.
WO2006014579A2 (en) 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences
ES2346072T3 (en) 2004-08-17 2010-10-08 Csl Behring Gmbh DEPENDENT MODIFIED POLYPEPTIDES OF VITAMIN K.
US7563612B2 (en) 2004-09-27 2009-07-21 Cornell Research Foundation, Inc. Recombinant bifunctional protein of human lutropin receptor and human chorionic gonadotropin B-subunit and uses thereof
RU2401842C2 (en) 2004-10-08 2010-10-20 Домантис Лимитед Antagonists and method of using said antagonists
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
PT1891105E (en) 2005-06-13 2012-06-27 Imp Innovations Ltd Oxyntomodulin analogues and their effects on feeding behaviour
US8759290B2 (en) 2005-10-18 2014-06-24 Biocon Limited Oral glucagon-like peptide conjugates for metabolic diseases
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9249407B2 (en) * 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8759292B2 (en) * 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
PT2101821E (en) * 2006-12-15 2014-10-03 Baxter Int Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
DE102007006189B4 (en) 2007-02-07 2009-07-30 Isotopen Technologien München AG Apparatus for filling a medical instrument with a radioactive substance and method
AT505262A1 (en) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und New recombinant angiotensin I converting enzyme 2 polypeptide comprising specific amount of glycosylated and sugar portion, useful for enzyme substitution therapy for treating acute respiratory distress syndrome or acute lung injury
US7741074B2 (en) 2007-12-05 2010-06-22 Novozymes, Inc. Polypeptides having endoglucanase activity and polynucleotides encoding same
CN102112157B (en) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 Conjugated proteins with prolonged in vivo efficacy
JP5765813B2 (en) 2008-09-19 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション Polymer conjugates of therapeutic peptides
EP2337585A1 (en) 2008-09-19 2011-06-29 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
CN102413990A (en) 2009-02-27 2012-04-11 钴领无限公司 Modular automated tool dispenser
CN102942626B (en) 2009-03-05 2015-11-04 江苏豪森医药集团有限公司 Glucagon-like peptide-2 analog and its production and use
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
FR2947181B1 (en) 2009-06-26 2012-05-04 Lfb Biotechnologies FACTOR VII COMPOSITION
DE102009031992A1 (en) 2009-07-06 2011-01-13 Paul Hartmann Ag Device for negative pressure therapy of wounds
US9663778B2 (en) * 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
EP2314616A1 (en) 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
AR079345A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli OXINTOMODULINE PEPTIDAL ANALOG
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
KR101382593B1 (en) 2010-07-21 2014-04-10 한미사이언스 주식회사 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
AU2012261869B2 (en) 2011-06-02 2017-01-05 Opko Biologics Ltd. Long-acting GLP-1/Glucagon receptor agonists
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
CN109306015B (en) 2011-06-17 2022-04-26 韩美科学株式会社 Conjugates comprising oxyntomodulin and immunoglobulin fragment and uses thereof
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
KR101895047B1 (en) 2011-12-30 2018-09-06 한미사이언스 주식회사 A site-specific GLP-2 conjugate using an immunoglobulin fragment
SG11201404836QA (en) * 2012-02-14 2014-12-30 Opko Biolog Ltd Long-acting coagulation factors and methods of producing same
WO2013157002A1 (en) 2012-04-19 2013-10-24 Prolor Biotech Inc. Long-acting oxyntomodulin variants and methods of producing same
SG11201408054RA (en) 2012-06-04 2015-01-29 Opko Biolog Ltd Pegylated oxm variants
US20150307865A1 (en) 2012-10-15 2015-10-29 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
EP2922867B1 (en) 2012-11-20 2021-07-21 OPKO Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
KR102527180B1 (en) * 2014-12-10 2023-04-27 옵코 바이오로직스 리미티드 Methods of producing long acting ctp-modified growth hormone polypeptides
PL3310347T3 (en) * 2015-06-19 2021-12-27 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CA3030533A1 (en) 2016-07-11 2018-01-18 Oren HERSHKOVITZ Long-acting coagulation factor vii and methods of producing same

Also Published As

Publication number Publication date
MX2019000554A (en) 2019-09-19
US11976106B2 (en) 2024-05-07
IL264208B1 (en) 2024-10-01
AU2024200950B2 (en) 2024-10-03
IL264208A (en) 2019-02-28
PT3481855T (en) 2023-11-27
BR112019000610A2 (en) 2019-07-02
CN109563145A (en) 2019-04-02
JP7319187B2 (en) 2023-08-01
CA3030533A1 (en) 2018-01-18
US20200354430A1 (en) 2020-11-12
CL2019000099A1 (en) 2019-04-12
AU2021269373A1 (en) 2021-12-16
EP4303228A3 (en) 2024-03-13
EP3481855B1 (en) 2023-09-06
AU2017296352A1 (en) 2019-02-21
EP3481855A1 (en) 2019-05-15
KR20240006077A (en) 2024-01-12
CN118085104A (en) 2024-05-28
ES2963725T3 (en) 2024-04-01
KR102618424B1 (en) 2023-12-26
KR20190039944A (en) 2019-04-16
EA201990255A1 (en) 2019-07-31
HUE064463T2 (en) 2024-03-28
TW201808988A (en) 2018-03-16
EP4303228A2 (en) 2024-01-10
IL315314A (en) 2024-10-01
AU2024200950A1 (en) 2024-03-07
SG10202100189WA (en) 2021-02-25
CN109563145B (en) 2024-01-26
JP2019530637A (en) 2019-10-24
WO2018011799A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201408054RA (en) Pegylated oxm variants
SG11201804915RA (en) Methods for treating huntington's disease
SG11201809064QA (en) Chimeric neurotoxins
SG11201811148SA (en) Cell penetrating peptide (cpp)-mediated ev loading
SG11201808108XA (en) Synthesis of indazoles
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201908456VA (en) Linker units and molecular constructs comprising same
SG11201908633SA (en) Kappa opioid receptor antagonists and products and methods related thereto
SG11201810687SA (en) Serum albumin-binding fibronectin type iii domains
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201809502YA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201903348UA (en) Therapeutic compounds and methods of use thereof
SG11201803732PA (en) Novel anti-angiogenic fusion polypeptides
SG11201903100TA (en) Method of preparing peptides comprising a lipophilically modified lysine side chain
SG11201811311VA (en) Compounds for imaging tau protein aggregates
SG11201903521XA (en) Pharmaceutical formulations and methods of making the same